Physician profile
Glory Joseph
NPI 1003271495
$2,076.98
in general payments reported to CMS, 2019-2025
23 companies · $256 in 2025
The $256 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $209 · 2023: $1,024 · 2024: $452 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,662 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,661.91 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $228.78 | 2023-2024 | |
| Novocure INC. | $224.93 | 2023 | Optune |
| Karyopharm Therapeutics INC. | $159.37 | 2023-2025 | Xpovio |
| Jazz Pharmaceuticals INC. | $148.84 | 2024 | |
| Janssen Biotech, INC. | $142.59 | 2023-2025 | Darzalex, Tecvayli |
| Stryker Corporation | $136.12 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $127.56 | 2022-2024 | Imfinzi |
| Tactile Systems Technology INC | $122.92 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Pfizer INC. | $118.47 | 2025 | |
| Mirati Therapeutics, INC. | $108.42 | 2023 | Krazati |
| Amgen INC. | $99.95 | 2022 | |
| Gt Medical Technologies, INC | $94.18 | 2023 | Gammatile |
| Adc Therapeutics America, INC. | $53.05 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $50.09 | 2023-2024 | Pluvicto |
| Rigel Pharmaceuticals, INC. | $50.00 | 2024 | Tavalisse, Rezlidhia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $35.01 | 2025 | |
| Lilly USA, LLC | $33.08 | 2024 | Jaypirca |
| Apellis Pharmaceuticals, INC. | $32.40 | 2023 | |
| Sumitomo Pharma America, INC. | $30.95 | 2023-2024 | Orgovyx |
| Regeneron Healthcare Solutions, INC. | $25.99 | 2024 | Libtayo |
| Eisai INC. | $20.45 | 2023 | |
| Merck Sharp & Dohme LLC | $18.99 | 2023 | Keytruda |
| Astellas Pharma US INC | $14.84 | 2024 | Xtandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glory Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.